Work

Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.tps2669

Authors: Matthew Reilley, Apostolia Maria Tsimberidou, Sarina Anne Piha-Paul, Timothy A Yap, Siqing Fu, Aung Naing, Jordi Rodon, Ly Minh Nguyen, Casey Ager, Martin Meng, Priyamvada Jayaprakash, Manuel Schmidt, Matthias Baumann, Funda Meric-Bernstam, Michael A. Curran, David S. Hong

Institutions: University of Virginia, The University of Texas MD Anderson Cancer Center, Mologen (Germany)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947938389

Cites:

Cited by: 13

Related to: 10